In the past, 131I therapy was routinely performed to destroy thyroid remnant tissue (i.e., thyroid remnant ablation) also in low-risk DTC patients with the aim to simplify the follow-up of such patients by increasing the specificity and accuracy of basal and/or stimulated Tg measurements [17,25]. The gene discussed is TG; the disease is thyroid gland disorder.